Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: Neuroprotection by CAST overexpression

Journal of Neuroscience

Volumn 28, Issue 47, 2008, Pages 12241-12254

  Rao, Mala V ^a,b   Mohan, Panaiyur S ^a,b   Peterhoff, Corrinne M ^a   Yang, Dun Sheng ^a,b   Schmidt, Stephen D ^a   Stavrides, Philip H ^a   Campbell, Jabbar ^a   Chen, Yuanxin ^a   Jiang, Ying ^a   Paskevich, Peter A ^c,d   Cataldo, Anne M ^c,d   Haroutunian, Vahram ^e   Nixon, Ralph A ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MCLEAN HOSPITAL   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Calpain; Caspase; Cdk5; ERK; Tau

Indexed keywords

CALPAIN; CALPAIN 2; CALPASTATIN; CASPASE 3; INTERLEUKIN 1BETA CONVERTING ENZYME; KAINIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEINASE; SHORT HAIRPIN RNA; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOSKELETON; DENDRITE; DISEASE COURSE; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; IN VIVO STUDY; MOUSE; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROFILAMENT; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; BRAIN; CALCIUM-BINDING PROTEINS; CALPAIN; CASE-CONTROL STUDIES; CASPASES; CELL DEATH; CELL LINE, TRANSFORMED; CYTOSKELETON; EXCITATORY AMINO ACID AGONISTS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; KAINIC ACID; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; NERVE DEGENERATION; POSTMORTEM CHANGES; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 58149397537     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.4119-08.2008     Document Type: Article

References (72)

1. Adamec E, Mohan P, Vonsattel JP, Nixon RA (2002) Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. Acta Neuropathol (Berl) 104:92-104.
2. Amadoro G, Ciotti MT, Costanzi M, Cestari V, Calissano P, Canu N (2006) NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. Proc Natl Acad Sci U S A 103:2892-2897.
3. Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y (2006) Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia 47:867-872.
4. Averna M, De Tullio R, Salamino F, Minafra R, Pontremoli S, Melloni E (2001) Age-dependent degradation of calpastatin in kidney of hypertensive rats. J Biol Chem 276:38426-38432.
5. Ayala-Grosso C, Tam J, Roy S, Xanthoudakis S, Da Costa D, Nicholson DW, Robertson GS (2006) Caspase-3 cleaved spectrin colocalizes with neurofilament-immunoreactive neurons in Alzheimer's disease. Neuroscience 141:863-874.
6. Barnoy S, Kosower NS (2007) Calpastatin in rat myoblasts: transient diminution and decreased phosphorylation depend on myogenin-directed myoblast differentiation. Int J Biochem Cell Biol 39:253-261.
7. Bartus RT, Elliott PJ, Hayward NJ, Dean RL, Harbeson S, Straub JA, Li Z, Powers JC (1995) Calpain as a novel target for treating acute neurodegenerative disorders. Neurol Res 17:249-258.
8. Battaglia F, Trinchese F, Liu S, Walter S, Nixon RA, Arancio O (2003) Calpain inhibitors, a treatment for Alzheimer's disease: position paper. J Mol Neurosci 20:357-362.
9. Carragher NO (2006) Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr Pharm Des 12:615-638.
10. Cataldo AM, Thayer CY, Bird ED, Wheelock TR, Nixon RA (1990) Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer's disease: evidence for a neuronal origin. Brain Res 513:181-192.
11. Cole AR, Noble W, van Aalten L, Plattner F, Meimaridou R, Hogan D, Taylor M, LaFrancois J, Gunn-Moore F, Verkhratsky A, Oddo S, LaFerla F, Giese KP, Dineley KT, Duff K, Richardson JC, Yan SD, Hanger DP, Allan SM, Sutherland C (2007) Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J Neurochem 103:1132-1144.
12. Crespo-Biel N, Canudas AM, Camins A, Pallàs M (2007) Kainate induces AKT, ERK and cdk5/GSK3beta pathway deregulation, phosphorylates tau protein in mouse hippocampus. Neurochem Int 50:435-442.
13. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40:471-483.
14. Dottavio-Martin D, Ravel JM (1978) Radiolabeling of proteins by reductive alkylation with [14C] formaldehyde and sodium cyanoborohydride. Anal Biochem 87:562-565.
15. Fifre A, Sponne I, Koziel V, Kriem B, Yen Potin FT, Bihain BE, Olivier JL, Oster T, Pillot T (2006) Microtubule-associated protein MAP1A, MAP1B, and MAP2 proteolysis during soluble amyloid beta-peptide-induced neuronal apoptosis. Synergistic involvement of calpain and caspase-3. J Biol Chem 281:229-240.
16. Franklin KBJ, Paxions G (1997) The mouse brain in stereotaxic coordinates. San Diego: Academic.
17. French ED, Aldinio C, Schwarcz R (1982) Intrahippocampal kainic acid, seizures and local neuronal degeneration: relationships assessed in unanesthetized rats. Neuroscience 7:2525-2536.
18. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL (2003) Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100:10032-10037.
19. Goll DE, Thompson VF, Taylor RG, Zalewska T (1992) Is calpain activity regulated by membranes and autolysis or by calcium and calpastatin? Bioessays 14:549-556.
20. Goll DE, Thompson VF, Li H, Wei W, Cong J (2003) The calpain system. Physiol Rev 83:731-801.
21. Grynspan F, Griffin WB, Mohan PS, Shea TB, Nixon RA (1997a) Calpains and calpastatin in SH-SY5Y neuroblastoma cells during retinoic acid-induced differentiation and neurite outgrowth: comparison with the human brain calpain system. J Neurosci Res 48:181-191.
22. Grynspan F, Griffin WR, Cataldo A, Katayama S, Nixon RA (1997b) Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Brain Res 763:145-158.
23. Han F, Shirasaki Y, Fukunaga K (2006) 3-[2-[4-(3-Chloro-2- methylphenylmethyl)-1-piperazinyl]ethyl]-5,6-dimethoxy -1-(4-imidazolylmethyl)- 1H-indazole dihydro-chloride 3.5 hydrate (DY-9760e) is neuroprotective in rat microsphere embolism: role of the cross-talk between calpain and caspase-3 through calpastatin. J Pharmacol Exp Ther 317:529-536.
24. Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, Rocca WA (1996) Dementia and adult-onset unprovoked seizures. Neurology 46:727-730.
25. Hitomi K, Yokoyama A, Maki M (1998) Expression of biologically active human calpastatin in baculovirus-infected insect cells and in Escherichia coli. Biosci Biotechnol Biochem 62:136-141.
26. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104:1433-1439.
27. Ishihara I, Minami Y, Nishizaki T, Matsuoka T, Yamamura H (2000) Activation of calpain precedes morphological alterations during hydrogen peroxide-induced apoptosis in neuronally differentiated mouse embryonal carcinoma P19 cell line. Neurosci Lett 279:97-100.
28. Jeon SH, Kim YS, Bae CD, Park JB (2000) Activation of JNK and p38 in rat hippocampus after kainic acid induced seizure. Exp Mol Med 32:227-230.
29. Julien JP, Mushynski WE (1998) Neurofilaments in health and disease. Prog Nucleic Acid Res Mol Biol 61:1-23.
30. Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S (2000) Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem 275:17166-17172.
31. Law A, Gauthier S, Quirion R (2001) Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against beta-amyloid toxicity. Br J Pharmacol 133:1114-1124.
32. Lee MS, Tsai LH (2003) Cdk5: one of the links between senile plaques and neurofibrillary tangles? J Alzheimers Dis 5:127-137.
33. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405:360-364.
34. Lee VM, Balin BJ, Otvos L Jr, Trojanowski JQ (1991) A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251:675-678.
35. Louzada PR, Lima AC, Mendonca-Silva DL, Noël F, De Mello FG, Ferreira ST (2004) Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. FASEB J 18:511-518.
36. Matsui T, Ramasamy K, Ingelsson M, Fukumoto H, Conrad C, Frosch MP, Irizarry MC, Yuan J, Hyman BT (2006) Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable abeta42 levels. J Neuropathol Exp Neurol 65:508-515.
37. Melloni E, Averna M, Stifanese R, De Tullio R, Defranchi E, Salamino F, Pontremoli S (2006) Association of calpastatin with inactive calpain: a novel mechanism to control the activation of the protease? J Biol Chem 281:24945-24954.
38. Mendez M, Lim G (2003) Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging 20:791-803.
39. Mohan PS, Nixon RA (1995) Purification and properties of high molecular weight calpastatin from bovine brain. J Neurochem 64:859-866.
40. Nilsson E, Alafuzoff I, Blennow K, Blomgren K, Hall CM, Janson I, Karlsson I, Wallin A, Gottfries CG, Karlsson JO (1990) Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue. Neurobiol Aging 11:425-431.
41. Nixon RA (2003) The calpains in aging and aging-related diseases. Ageing Res Rev 2:407-418.
42. Pareek TK, Keller J, Kesavapany S, Pant HC, Iadarola MJ, Brady RO, Kulkarni AB (2006) Cyclin-dependent kinase 5 activity regulates pain signaling. Proc Natl Acad Sci U S A 103:791-796.
43. Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, Park H, Moran TM, Chan JY, Buxbaum JD (2001) Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol 58:2025-2032.
44. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615-622.
45. Plattner F, Angelo M, Giese KP (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281:25457-25465.
46. Pompl PN, Yemul S, Xiang Z, Ho L, Haroutunian V, Purohit D, Mohs R, Pasinetti GM (2003) Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease. Arch Neurol 60:369-376.
47. Rao MV, Garcia ML, Miyazaki Y, Gotow T, Yuan A, Mattina S, Ward CM, Calcutt NA, Uchiyama Y, Nixon RA, Cleveland DW (2002) Gene replacement in mice reveals that the heavily phosphorylated tail of neurofilament heavy subunit does not affect axonal caliber or the transit of cargoes in slow axonal transport. J Cell Biol 158:681-693.
48. Saito K, Elce JS, Hamos JE, Nixon RA (1993) Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A 90:2628-2632.
49. Schmidt SD, Jiang Y, Nixon RA, Mathews PM (2005) Tissue processing prior to protein analysis and amyloid-beta quantitation. Methods Mol Biol 299:267-278.
50. Shea TB, Spencer MJ, Beermann ML, Cressman CM, Nixon RA (1996) Calcium influx into human neuroblastoma cells induces ALZ-50 immunoreactivity: involvement of calpain-mediated hydrolysis of protein kinase C. J Neurochem 66:1539-1549.
51. Shi Y, Melnikov VY, Schrier RW, Edelstein CL (2000) Downregulation of the calpain inhibitor protein calpastatin by caspases during renal ischemia-reperfusion. Am J Physiol Renal Physiol 279:F509-F517.
52. Shiurba RA, Ishiguro K, Takahashi M, Sato K, Spooner ET, Mercken M, Yoshida R, Wheelock TR, Yanagawa H, Imahori K, Nixon RA (1996) Immunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer pathology. Brain Res 737:119-132.
53. Siman R, Noszek JC, Kegerise C (1989) Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J Neurosci 9:1579-1590.
54. Siman R, Reaume AG, Savage MJ, Trusko S, Lin YG, Scott RW, Flood DG (2000) Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J Neurosci 20:8717-8726.
55. Takano J, Tomioka M, Tsubuki S, Higuchi M, Iwata N, Itohara S, Maki M, Saido TC (2005) Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J Biol Chem 280:16175-16184.
56. Takashima A, Murayama M, Yasutake K, Takahashi H, Yokoyama M, Ishiguro K (2001) Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci Lett 306:37-40.
57. Tandon A, Yu H, Wang L, Rogaeva E, Sato C, Chishti MA, Kawarai T, Hasegawa H, Chen F, Davies P, Fraser PE, Westaway D, St George-Hyslop PH (2003) Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles. J Neurochem 86:572-581.
58. Taniguchi S, Fujita Y, Hayashi S, Kakita A, Takahashi H, Murayama S, Saido TC, Hisanaga S, Iwatsubo T, Hasegawa M (2001) Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Lett 489:46-50.
59. Thornberry NA (1994) Interleukin-1 beta converting enzyme. Methods Enzymol 244:615-631.
60. Vaisid T, Kosower NS, Barnoy S (2005) Caspase-1 activity is required for neuronal differentiation of PC12 cells: cross-talk between the caspase and calpain systems. Biochim Biophys Acta 1743:223-230.
61. Veeranna, Kaji T, Boland B, Odrljin T, Mohan P, Basavarajappa BS, Peterhoff C, Cataldo A, Rudnicki A, Amin N, Li BS, Pant HC, Hungund BL, Arancio O, Nixon RA (2004) Calpain mediates calcium-induced activation of the erk1,2 MAPK pathway and cytoskeletal phosphorylation in neurons: relevance to Alzheimer's disease. Am J Pathol 165:795-805.
62. Vitto A, Nixon RA (1986) Calcium-activated neutral proteinase of human brain: subunit structure and enzymatic properties of multiple molecular forms. J Neurochem 47:1039-1051.
63. Wang KK, Posmantur R, Nadimpalli R, Nath R, Mohan P, Nixon RA, Talanian RV, Keegan M, Herzog L, Allen H (1998) Caspase-mediated fragmentation of calpain inhibitor protein calpastatin during apoptosis. Arch Biochem Biophys 356:187-196.
64. Wang Q, Yu S, Simonyi A, Sun GY, Sun AY (2005) Kainic acid-mediated excitotoxicity as a model for neurodegeneration. Mol Neurobiol 31:3-16.
65. Wei W, Fareed MU, Evenson A, Menconi MJ, Yang H, Petkova V, Hasselgren PO (2005) Sepsis stimulates calpain activity in skeletal muscle by decreasing calpastatin activity but does not activate caspase-3. Am J Physiol Regul Integr Comp Physiol 288:R580-R590.
66. Wingrave JM, Sribnick EA, Wilford GG, Matzelle DD, Mou JA, Ray SK, Hogan EL, Banik NL (2004) Higher calpastatin levels correlate with resistance to calpain-mediated proteolysis and neuronal apoptosis in juvenile rats after spinal cord injury. J Neurotrauma 21:1240-1254.
67. Wu HY, Lynch DR (2006) Calpain and synaptic function. Mol Neurobiol 33:215-236.
68. Xu W, Wong TP, Chery N, Gaertner T, Wang YT, Baudry M (2007) Calpain-mediated mGluR1alpha truncation: a key step in excitotoxicity. Neuron 53:399-412.
69. Yoo BC, Lubec G (2001) p25 protein in neurodegeneration. Nature 411:763-764.
70. Zaczek R, Nelson M, Coyle JT (1981) Kainic acid neurotoxicity and seizures. Neuropharmacology 20:183-189.
71. Zhang C, Siman R, Xu YA, Mills AM, Frederick JR, Neumar RW (2002) Comparison of calpain and caspase activities in the adult rat brain after transient forebrain ischemia. Neurobiol Dis 10:289-305.
72. Zhu SG, Sheng JG, Jones RA, Brewer MM, Zhou XQ, Mrak RE, Griffin WS (1999) Increased interleukin-1beta converting enzyme expression and activity in Alzheimer disease. J Neuropathol Exp Neurol 58:582-587.